Israel & Canada Move Ahead, while US Lags Behind in Medical Marijuana Research

Posted by 21pc on January 23, 2008
Earlier this month, there were two exciting developments for medical cannabis internationally. In Israel, a Tel Aviv medical clinic began dispensing medical cannabis to patients in need, while in Canada, a federal court ruling ended the monopoly a federal contractor has on supplying cannabis to patients, opening up possibilities for dispensaries and collective production of medicine. Our international counterparts may be surging ahead in their paths to provide safe access for patients who benefit from medical cannabis, but here in the US, it's sometimes hard to move to the conversation about access when our government barely budges on research issues. The DEA continues to uphold a monopoly on the production of cannabis for research, even though it's own administrative law judge recommended ending this monopoly by granting a license to Professor Lyle Craker to grow research material. While whole plant medical cannabis is being stonewalled though, GW Pharmaceuticals is moving rapidly through Phase III trials in the US for Sativex, a cannabis-based tincture. GW's chairman, Dr. Geoffrey Guy, had this to say about the progress of Sativex:
"2008 promises to be an equally eventful year for GW, with the results of a number of key Sativex Phase III trials in Europe and the US due to be reported. The momentum behind Sativex and the wider field of cannabinoid medicines, as highlighted today by the promising results of our THCV metabolic research programme, continues to grow..."
It's good to know that GW recognizes the potential for a wider field of cannabis medicine, but until the monopoly on production of cannabis for research is ended, it will be difficult for researchers to push this field forward in the United States. Until then, at least patients in Israel are happy: "One cancer patient said the ministry's decision to offer the drug through the clinic was "a blessing," saying it prevents suffering patients from being driven to buy the drug illegally."